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Background: The circulating soluble TNF-like weak inducer of apoptosis (sTWEAK) is a cytokine that modulates
inflammatory and atherogenic reactions related to cardiometabolic risk. We investigated the association
between sTWEAK levels and metabolic syndrome (MetS) and its components in older subjects at high
cardiovascular risk.
Methods: Cross-sectional analysis of 452 non-diabetic individuals (men and women aged 55–80 years) at high
cardiovascular risk. MetS was defined by AHA/NHLBI and IDF criteria. Logistic regression analyses were used to estimate
odds ratios (ORs) for MetS and its components by tertiles of serum sTWEAK concentrations measured by ELISA.
Results: sTWEAK concentrations were lower in subjects with MetS than in those without. In gender- and age-adjusted
analyses, subjects in the lowest sTWEAK tertile had higher ORs for overall MetS [1.71 (95% CI, 1.07-2.72)] and its
components abdominal obesity [2.01 (1.15-3.52)], hyperglycemia [1.94 (1.20-3.11)], and hypertriglyceridemia [1.73 (1.05-
2.82)] than those in the upper tertile. These associations persisted after controlling for family history of diabetes and
premature coronary heart disease, lifestyle, kidney function and other MetS components. sTWEAK concentrations
decreased as the number of MetS components increased. Individuals in the lowest vs the upper sTWEAK tertile had an
increased risk of disclosing greater number of MetS features. Adjusted ORs for individuals with 2 vs ≤1, 3 vs ≤1, and ≥4
vs≤ 1 MetS components were 2.60 (1.09-6.22), 2.83 (1.16-6.87) and 6.39 (2.42-16.85), respectively.
Conclusion: In older subjects at high cardiovascular risk, reduced sTWEAK levels are associated with MetS: abdominal
obesity, hypertriglyceridemia and hyperglycemia are the main contributors to this association.
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The TNF-like weak inducer of apoptosis (TWEAK) is a
molecule of the TNF superfamily [1,2]. It is initially
expressed as a type-II trans-membrane protein (mTWEAK),
but a smaller biologically active form can also be shed into
the circulation as a soluble form (sTWEAK). TWEAK is
ubiquitously expressed in a variety of organs, tissues and
cell types, with high levels in heart, brain, pancreas,* Correspondence: jordi.salas@urv.cat
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article, unless otherwise stated.skeletal muscle and adipose tissues, and lower levels in
liver and kidney. The binding of sTWEAK to its receptor,
the fibroblast growth factor-inducible 14 (Fn14), mediates
multiple biological effects, including proinflammatory
cytokine induction, angiogenesis, and the regulation of cell
survival, proliferation and death [3,4].
In recent years, cross-sectional studies investigating
the associations between sTWEAK and diseases and/or
metabolic disorders have been widely reported. In this
context, Blanco-Colio et al. reported lower levels of
sTWEAK in patients with atherosclerosis and a negative
correlation between circulating TWEAK levels and the
intima/media thickness in asymptomatic subjects [5].
Similarly, circulating sTWEAK levels have been found totral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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orders [6-11]. Decreased sTWEAK levels have also been
related to a higher risk of endothelial dysfunction in sub-
jects with chronic kidney disease [12], and to long-term
cardiovascular mortality in patients with peripheral ar-
tery disease (PAD) [13]. And circulating sTWEAK con-
centrations have been negatively correlated with such
other laboratory and clinical parameters as fasting plasma
glucose levels, insulin resistance assessed by homeostasis
model assessment of insulin resistance (HOMA-IR) and
systolic or diastolic blood pressure in patients with type 2
diabetes (T2D) and in chronic kidney disease [10,14]. Fi-
nally, our group has demonstrated that patients with type
1 diabetes (T1D) had lower sTWEAK levels than healthy
subjects [15], and a negative association between sTWEAK
levels, glucose metabolism-related parameters and T2D in-
cidence has been reported [16].
To date, the relationship between circulating sTWEAK
levels and Metabolic Syndrome (MetS) has not been ex-
plored. Based on recent researches, we hypothesized that
low serum sTWEAK levels are associated with MetS, a
common metabolic disorder, resulting from abdominal
obesity and insulin resistance [17]. Thus, the present
study aimed to explore whether circulating sTWEAK
concentrations are associated with MetS and its individ-
ual components in elderly subjects at high cardiovascu-
lar risk.
Methods
Study design and participants
The present cross-sectional study was carried out on 452
Caucasian individuals at high risk for coronary heart dis-
ease (CHD), recruited by their medical practitioners from
three Spanish centers (Reus, Barcelona and Pamplona)
within the framework of the PREDIMED study [18], which
were randomly selected from those without diabetes at
baseline. The participants studied were community-
dwelling men and women aged 55–80 years. The exclu-
sion criteria included: prior cardiovascular disease (CVD)
(including coronary heart disease [angina, myocardial in-
farction, coronary revascularization procedures or exist-
ence of abnormal Q waves in the electrocardiogram],
stroke [either ischemic or hemorrhagic, including transi-
ent ischemic attacks], or clinical peripheral artery disease
with symptoms of intermittent claudication), prevalent
diabetes or treatment with insulin or oral hypoglycemic
drugs, immunodeficiency or HIV-positive status, illegal
drug use or chronic alcoholism, and/or body mass index
(BMI) >40 kg/m2. All participants had at least three of the
following cardiovascular risk factors: smoking, hyperten-
sion (systolic blood pressure ≥140 mmHg or diastolic
blood pressure ≥90 mmHg or under antihypertensive
medication), high low-density lipoprotein (LDL)-choles-
terol (≥160 mg/dl), low high-density lipoprotein (HDL)-cholesterol (≤40 mg/dl independently of lipid-lowering
therapy), overweight/obesity (BMI ≥25 kg/m2), or family
history of early-onset CHD.
The study was conducted in agreement with the Dec-
laration of Helsinki. The study protocol was approved by
the institutional review boards of the three centers in-
volved, and all subjects agreed to participate in the study
and gave their informed consent.Clinical and anthropometric information
Medical information was collected on subjects’ medical
record of a 47-item questionnaire about education, life-
style, history of illnesses and medication use. We also
administered a semiquantitative 137-item validated food
frequency questionnaire [19] and a validated Spanish
version of the Minnesota Leisure Time Physical Activity
Questionnaire to assess physical activity [20]. In addition,
anthropometric variables such as weight, height and waist
circumference (midway between the lower rib and the su-
perior border of the iliac crest) and blood pressure mea-
sured in triplicate using a validated semi-automatic
oscillometer (Omron HEM-705CP, Hoofddorp, Netherlands)
were determined by trained staff [21].Laboratory measurements
Blood samples were collected from all participants after
an overnight fast. The aliquots of serum and EDTA
plasma were immediately processed at 4°C, coded, and
shipped to a central laboratory in a portable cooler, and
stored at -80°C until analysis. The time between blood
sampling and freezing was less than one hour. Plasma
levels of fasting glucose and serum levels of total choles-
terol, HDL-cholesterol and triglycerides were measured
by routine laboratory tests using standard enzymatic
methods. LDL-cholesterol concentrations were calcu-
lated using Friedewald’s equation. Serum and urinary
creatinine, and urinary albumin concentrations were
determined by the modified Jaffé colorimetric method
and by the Bromcresol green albumin (BCG) method,
respectively.
The urinary albumin (mg/L)-to-creatinine (mg/dL) ra-
tio (ACR) was calculated and is reported in milligrams
per gram. On the basis of serum creatinine concentra-
tion measurements, the glomerular filtration rate was
estimated (eGFR) by the CKD-EPI (Chronic Kidney Dis-
ease Epidemiology Collaboration) equation for Caucasians
[22] as a measure of kidney function. sTWEAK concentra-
tions were determined in duplicate, in serum samples that
had never suffered any previous thaw cycle, by ELISA
using the commercially available, human TWEAK/
TNFSF12 kit #DY1090 (R&D Systems Europe, Abingdon,
Oxon, UK). The intra- and inter-assay coefficients of vari-
ation were 2.5% and 7.0%, respectively.
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The definition of MetS that we used was the new one by
the International Diabetes Federation (IDF) and the
American Heart Association/National Heart, Lung, and
Blood Institute (AHA/NHLBI), which has harmonized
previous definitions [23]. According to this definition, a
diagnosis of MetS requires the presence of at least three
of the following five components or risk factors: (1) ab-
dominal obesity measured by waist circumference accord-
ing to different ethnic groups by gender; (2) hypertension
(systolic and/or diastolic blood pressures ≥130/85 mmHg
or antihypertensive drug treatment); (3) low HDL-
cholesterol levels [fasting serum HDL-cholesterol levels
<40 mg/dL (1.03 mmol/L) in men and <50 mg/dL
(1.3 mmol/L) in women or drug treatment for reduced
HDL-C; (4) hypertriglyceridemia [fasting serum triglycer-
ides ≥150 mg/dL (1.7 mmol/L) or taking triglyceride-
lowering medication]; and (5) hyperglycemia [fasting
plasma glucose level ≥100 mg/dL (≥5.5 mmol/L) or drug
treatment for elevated glucose levels].
Statistical analysis
Analyses were performed using the SPSS software ver-
sion 19.0 (SPSS Inc, Chicago, IL). General characteristics
of the study population are presented by MetS status
and were compared using independent t-tests for con-
tinuous variables and Pearson χ2 tests for dichotomous
variables. The distribution of variables was tested using the
Kolmogorov–Smirnov tests. Skewed variables (sTWEAK,
triglyceride and plasma fasting glucose levels) were loge-
transformed prior to statistical analyses to approximate a
normal distribution. All the data are presented either as
means ± standard deviation (SD) for symmetric continuous
variables, median and inter quartile range for skewed con-
tinuous variables, or numbers and percentages for dichot-
omous variables. Age- and gender-adjusted partial Pearson
correlation analysis was used to study the relationships be-
tween serum sTWEAK concentration and each of the
MetS components (all as continuous variables).
Binary logistic regression analysis was used to estimate
the odds ratios (ORs) and 95% confidence intervals (CI)
for the prevalence of MetS, its components separately,
and the MetS score [sum of MetS components for each
individual (≤1 to ≥4)] by sTWEAK tertiles. The upper
sTWEAK tertile was considered as the reference cat-
egory. For the regression analyses several models were
fitted, controlling for the following potential con-
founders: Model 1 was adjusted for gender and age.
Model 2 was additionally adjusted for family history of
diabetes and premature CHD (yes/no), educational level
(primary education vs secondary/higher education), alco-
hol intake (g/d), smoking (current/not current), physical
activity [sedentary (≤200 METs-min/d) vs active (>200
METs-min/d)] and eGFR. A third model was also fittedto assess the associations between tertiles of sTWEAK
concentrations and each individual component of the
MetS. This model was additionally adjusted for the above-
mentioned model 2 and for the other components of
MetS as dichotomized variables (model 3). Effect modifi-
cation by gender was evaluated and tested by adding the
product term of serum sTWEAK concentration*gender to
the univariate model. The models were not stratified by
gender because no significant interactions between
sTWEAK and gender on MetS or its components were
detected (all P-values >0.05). Linear trend tests were cal-
culated using the median serum sTWEAK concentrations
of each category, which were then introduced into the
models as a continuous variable. All statistical tests were
two-tailed and the significance level was set at P <0.05.
Results
Table 1 presents the general characteristics of the study
populations stratified by MetS status. In all the individ-
uals (n = 452; mean age, 66 ± 6 year) – 214 men and 238
women – the prevalence of MetS was 51.8% (234/452).
Those with MetS exhibited significantly higher mean
BMI, waist circumference, and systolic and/or diastolic
blood pressure than those without. They also had signifi-
cantly higher levels of serum triglycerides and plasma
glucose. In contrast, individuals with MetS had signifi-
cantly lower HDL-cholesterol levels and serum sTWEAK
concentrations than those subjects without MetS (Table 1).
The age- and gender-adjusted partial correlation analysis
in the whole population showed that sTWEAK concentra-
tions were negatively related to waist circumference (r =
−0.13, p =0.005), fasting plasma glucose (r = −0.16, p <
0.001), and serum triglyceride levels (r = −0.10, p =0.03).
No relationship between sTWEAK concentrations and
HDL-cholesterol levels, or systolic and/or diastolic blood
pressure was found (data not shown). We also used the
same partial correlation analysis to assess the relationship
between sTWEAK concentrations and such markers of
kidney function as urinary ACR (ACR data was available
for only 246 participants) and eGFR. No relationship was
found between sTWEAK and ACR (r = 0.05; P =0.42).
However, a weak inverse relationship was observed be-
tween sTWEAK and eGFR (r = −0.14; P = 0.003). Even so,
we included this variable in the model as a confounder.
Binary logistic regression analyses are reported in
Tables 2, 3 and 4. The prevalence of MetS according to
sTWEAK levels in the lowest, middle, and highest tertile
decreased from 59.3 to 49.7 and 46.4%, respectively. In
the crude analysis, individuals in the lower sTWEAK ter-
tile had a significant higher risk of MetS than subjects in
the upper tertile [OR, 1.69 (95% CI, 1.06 - 2.66); P for
trend = 0.024]. After adjustments for relevant con-
founders (such as gender, age, family history of diabetes
and premature CHD, education, smoking, alcohol intake,
Table 1 General characteristics of the study population stratified for the presence and absence of MetS
Baseline variable MetS Non-MetS P value*
n 234 218
Age, years 66 ± 6 67 ± 6 0.30
Men, % (n) 47 (103) 47 (111) 1.00
BMI, kg/m2 30.6 ± 2.9 29.2 ± 3.0 <0.001
Overweight/obesity (BMI ≥25 kg/m2), % (n) 97 (228) 94 (206) 0.14
Waist circumference, cm 102.6 ± 8.8 96.5 ± 9.8 <0.001
Smoking habits
Current smoker, % (n) 23 (54) 22 (48) 0.82
Non-smoker, % (n) 77 (180) 78 (170)
Physical activity, METS-min/d 255.2 ± 205.8 289.0 ± 265.0 0.13
Educational level
Primary education, % (n) 69 (160) 71 (154) 0.61
Secondary or higher education, % (n) 31 (74) 29 (64)
Family history of diabetes, % (n) 31 (73) 25 (55) 0.17
Family history of premature CHD, % (n) 16 (38) 18 (41) 0.49
Diastolic blood pressure, mmHg 88.6 ± 10.4 84.2 ± 10.0 <0.001
Systolic blood pressure, mmHg 155.5 ± 20.5 149.0 ± 19.2 <0.001
LDL-cholesterol, mg/dL 137.8 ± 32.2 140.6 ± 31.8 0.35
HDL-cholesterol, mg/dL 50.8 ± 12.0 59.4 ± 14.0 <0.001
Triglyceride, mg/dL† 159.0 (116.0, 208.0) 107.0 (82.0, 130.0) <0.001
Fasting glucose, mg/dL† 105.3 (97.0, 117.6) 91.0 (86.0, 97.0) <0.001
sTWEAK, pg/mL† 543.0 (367.3, 751.2) 595.6 (418.6, 844.5) 0.014
Urinary ACR (mg/g) 18.1 ± 31.9 12.7 ± 30.3 0.17
eGFR (ml/min/1.73 m2) 74.0 ± 14.9 75.5 ± 15.3 0.29
Metabolic syndrome components
Abdominal obesity, % (n) 88 (207) 53 (115) <0.001
Hyperglycemia, % (n) 69 (161) 10 (22) <0.001
Hypertriglyceridemia, % (n) 60 (141) 6 (14) <0.001
Low HDL-cholesterol level, % (n) 37 (88) 5 (12) <0.001
Hypertension, % (n) 99 (233) 94 (206) 0.001
Data expressed as mean ± SD, or % (number). Abbreviations: MetS Metabolic Syndrome, BMI body mass index, METs Metabolic Equivalents, CHD coronary heart disease,
LDL low-density lipoprotein, HDL high-density lipoprotein, sTWEAK soluble TNF-like weak inducer of apoptosis, ACR Albumin–creatinine ratio (ACR data was available
only for 246 participants; n = 129 in MetS group and n = 117 in Non-MetS group), eGFR estimated glomerular filtration rate. †Values expressed as median with inter
quartile range. *P value for comparisons between two groups was tested by χ2 test for categorical variables or Student’s t-test for continuous variables.
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ciations did not appreciably change [1.85 (1.15 - 3.00); P
for trend = 0.011]. A similar and significant inverse asso-
ciation between sTWEAK and prevalence of MetS was
observed when the sTWEAK was analyzed as a continu-
ous variable [1.49 (1.13 - 1.98) per unit decrease in esti-
mated log sTWEAK] (Table 2).
Similarly, after adjusting for model 2 mentioned above,
compared to the subjects in the upper sTWEAK tertile,
those in the lower tertile had an increased risk of the ab-
dominal obesity, hyperglycemia, and hypertriglyceridemia
components of the MetS [2.03 (1.14 - 3.60), P for trend
0.013; 1.95 (1.20- 3.19), P for trend 0.007; 1.97 (1.18-3.30),P for trend 0.041, respectively]. These associations were
slightly attenuated but remained significant after add-
itional adjustment for the others MetS components
(model 3). Nevertheless, sTWEAK was not associated
with the prevalence of such components of the MetS as
low HDL-cholesterol and hypertension (Table 3).
A total of 13.7% of the total study population had one
or no components of the MetS, 34.5% had two, 28.8%
had three, and 23.0% had four or more. Serum sTWEAK
concentrations decreased when the number of MetS
components (MetS score) was increased. The median
sTWEAK concentrations in the following categories: ≤1,
2, 3, and ≥4 MetS components were 615.6, 587.5, 555.7,
Table 2 Odds ratio and 95% CI for MetS according to tertiles of serum sTWEAK concentrations
Tertiles of sTWEAK concentrations
Continuous‡
1st tertile 2nd tertile 3rd tertile P value
for trend*<453.1 ng/mL 453.1 to 706.4 < ng/mL ≥706.4 ng/mL
No. of MetS/No. of non-MetS 234/218 89/61 75/76 70/81
Crude model 1.39 (1.06 - 1.82) 1.69 (1.06 - 2.66) 1.14 (0.73 - 1.79) 1.00 [Ref.] 0.024
Model 1 1.40 (1.07 - 1.84) 1.71 (1.07 - 2.72) 1.15 (0.72 - 1.82) 1.00 [Ref.] 0.022
Model 2 1.49 (1.13 - 1.98) 1.85 (1.15 - 3.00) 1.21 (0.75 - 1.94) 1.00 [Ref.] 0.011
Results expressed as odds ratios (95% CI) for MetS from logistic regression analysis. Abbreviations: MetS Metabolic Syndrome, sTWEAK soluble TNF-like weak
inducer of apoptosis.
Crude model: unadjusted; Model 1: Adjusted for gender and age; Model 2: Additionally adjusted for family history of diabetes and premature CHD (yes/no),
educational level (primary education vs secondary/higher education), alcohol intake (g alcohol/d), smoking (current/not-current), physical activity (sedentary vs
active) and eGFR. ‡Per unit decrease in log sTWEAK. *Linear trend tests were calculated using the median serum sTWEAK concentrations of each category and
using them as a new continuous variable in the models.
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Table 4 shows the ORs for the MetS score associated
with the presence of two, three, and four or more MetS
components compared with the presence of one or no
components, according to sTWEAK tertiles. In the full
model (model 2), individuals in the lowest vs the upper
sTWEAK tertile had an increased risk of having a
greater number of MetS components.
Discussion
In this cross-sectional study conducted on community-
dwelling elderly subjects at high cardiovascular risk, we
report for the first time that low sTWEAK concentrations
were associated with increased risk of MetS, independent
of several confounders. Abdominal obesity, hyperglycemia
and hypertriglyceridemia were the main contributors to
this association. These findings add new knowledge to the
current scientific literature, and suggest that sTWEAK
may have a role in metabolic disorders such as MetS.
Overall, almost all the available studies have confirmed
that patients with CVD or CVD-related diseases have
decreased sTWEAK concentrations. In previous studies,
a reduced concentration of sTWEAK has been described
in patients with such pathological conditions as chronic
heart failure [6], coronary and peripheral arterial disease
[7-9], hypertension [11], T1D and T2D, and/or end-stage
renal failure [10,15,16]. These data are in agreement with
the findings of our study, which indicated a link between
low sTWEAK concentrations and MetS, a cluster of
metabolic disorders which predispose to the develop-
ment of T2D and atherosclerosis, and increase the risk
of CVD [24]. In line with this, several authors have sug-
gested that reduced levels of sTWEAK might serve as a
novel biomarker of atherosclerosis [5,10]. In fact, it has
recently been reported that low sTWEAK levels were as-
sociated with long-term cardiovascular mortality in
symptomatic PAD patients [13], and could be considered
as a predictor of future cardiovascular outcomes in non-
dialysis CKD patients [25]. It is also important to mentionthat in our study as the number of MetS components in-
creased, the sTWEAK values gradually decreased. In keep-
ing with these observations, we found that individuals
with lower sTWEAK levels were more likely to have more
MetS components. Thus, the consideration of sTWEAK
as an indicative biomarker of risk factors for CVD is rein-
forced by our findings in MetS patients. Although our
data support the possible existence of etiological associa-
tions, the biological mechanisms through which low
sTWEAK levels were related to MetS remain speculative.
Obesity-induced inflammation might be one of the mech-
anisms explaining the observed association in our study.
Vendrell et al. [26] reported that TWEAK and Fn14
gene expression were higher in the adipose tissue of se-
verely obese patients than in controls, and that inflam-
matory stimuli in vitro induced by lipopolysaccharide
and TNFα up-regulated TWEAK in THP-1 macrophages
and Fn14 expression in SGBS adipocyte cells, respect-
ively [26]. Despite the moderate inflammatory capacity
of the sTWEAK cytokine over the adipocyte, a competi-
tive interfering activity with TNFα signalling in the
adipocyte has been described [27,28]. An imbalance of
sTWEAK forms (membrane bound mTWEAK and soluble
sTWEAK) in the obese state may help potentiate the in-
flammatory effect of TNFα over the adipocyte.
Our finding that lower sTWEAK concentrations were
related with abdominal obesity agrees with the data ob-
tained by Maymó-Masip et al. [27], which show that
sTWEAK levels in severely obese patients are lower than
in controls, and that their concentration increases after
weight loss. This may suggest that sTWEAK plays an
anti-inflammatory role in this setting, although add-
itional in vivo and in vitro studies are required. More-
over, in the case of severely obese individuals they found
that the main determinant of the sTWEAK circulating
levels was BMI, in an inverse-dependent manner [27].
There is no clear explanation for the mechanisms lead-
ing to lower levels of sTWEAK in individuals with MetS.
The rationale that low levels of sTWEAK, unlike other
Table 3 Odds ratio and 95% CI for the individual components of the MetS according to tertiles of serum sTWEAK
concentrations
Tertiles of sTWEAK concentrations
Effects on components of the MetS 1st tertile 2nd tertile 3rd tertile P value
for trend*<453.1 ng/mL 453.1 to <706.4 ng/mL ≥706.4 ng/mL
Abdominal obesity
No. abdominal obesity/No. non abdominal obesity 120/30 94/57 108/43
Crude model 1.60 (0.93 - 2.71) 0.65 (0.40 - 1.06) 1.00 [Ref.] 0.091
Model 1 2.01 (1.15 - 3.52) 0.86 (0.51 - 1.43) 1.00 [Ref.] 0.012
Model 2 2.03 (1.14 - 3.60) 0.88 (0.52 - 1.47) 1.00 [Ref.] 0.013
Model 3 1.85 (1.03 - 3.33) 0.87 (0.51 - 1.47) 1.00 [Ref.] 0.036
Hyperglycemia
No. hyperglycemia/No. non hyperglycemia 74/76 60/91 49/102
Crude model 2.03 (1.27 - 3.23) 1.37 (0.86 - 2.19) 1.00 [Ref.] 0.003
Model 1 1.94 (1.20 - 3.11) 1.29 (0.80 - 2.09) 1.00 [Ref.] 0.006
Model 2 1.95 (1.20 - 3.19) 1.37 (0.84 - 2.24) 1.00 [Ref.] 0.007
Model 3 1.71 (1.04 - 2.83) 1.37 (0.82 - 2.27) 1.00 [Ref.] 0.037
Hypertriglyceridemia
No. hypertriglyceridemia/No. nonhypertriglyceridemia 60/90 54/97 41/110
Crude model 1.79 (1.10 - 2.90) 1.49 (0.92 - 2.46) 1.00 [Ref.] 0.021
Model 1 1.73 (1.05 - 2.82) 1.40 (0.85 - 2.31) 1.00 [Ref.] 0.031
Model 2 1.97 (1.18 - 3.30) 1.44 (0.86 - 2.42) 1.00 [Ref.] 0.010
Model 3 1.68 (1.02 - 2.79) 1.36 (0.82 - 2.26) 1.00 [Ref.] 0.041
Low HDL-cholesterol
No. low HDL-cholesterol/No. non low HDL-cholesterol 31/119 31/120 38/113
Crude model 0.77 (0.45 - 1.33) 0.76 (0.44 - 1.31) 1.00 [Ref.] 0.355
Model 1 0.81 (0.47 - 1.41) 0.81 (0.47 - 1.42) 1.00 [Ref.] 0.478
Model 2 0.86 (0.48 - 1.52) 0.82 (0.46 - 1.46) 1.00 [Ref.] 0.614
Model 3 0.67 (0.36 - 1.24) 0.71 (0.39 - 1.29) 1.00 [Ref.] 0.207
Hypertension
No. hypertension/No. non hypertension 148/2 143/8 148/3
Crude model 1.50 (0.25 - 9.10) 0.36 (0.09 - 1.39) 1.00 [Ref.] 0.697
Model 1 1.51 (0.25 - 9.30) 0.37 (0.09 - 1.47) 1.00 [Ref.] 0.653
Model 2 1.67 (0.25 - 11.26) 0.33 (0.08 - 1.36) 1.00 [Ref.] 0.619
Model 3 1.22 (0.18 - 8.42) 0.33 (0.07 - 1.41) 1.00 [Ref.] 0.929
Results expressed as odds ratios (95% CI) for MetS components from logistic regression analysis. Abbreviations: MetS Metabolic Syndrome, sTWEAK soluble TNF-like weak
inducer of apoptosis.
Crude model: unadjusted; Model 1: Adjusted for gender and age; Model 2: Additionally adjusted for family history of diabetes and premature CHD (yes/no),
educational level (primary education vs secondary/higher education), alcohol intake (g alcohol/d), smoking (current/not-current), physical activity (sedentary vs
active) and eGFR; Model 3: Additionally adjusted for the presence of abdominal obesity (except for abdominal obesity), hyperglycemia (except for hyperglycemia),
hypertriglyceridemia (except for hypertriglyceridemia), low HDL-cholesterol (except for low HDL-cholesterol), hypertension (except for hypertension). *Linear trend
tests were calculated using the median serum sTWEAK concentrations of each category and using them as a new continuous variable in the models.
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tions associated with increased chronic inflammatory ac-
tivity is incompletely understood. Several conceivable
explanations have been proposed. For instance, sTWEAK
may have a beneficial effect on the regulation of the im-
mune response because it has been shown that TWEAK-
deficiency in mice leads to overabundant natural killercells and hypersensitivity to bacterial endotoxin, with an
excess of interferon-γ and IL-12 production from innate
immune cells. Furthermore, sTWEAK inhibits the activa-
tion of the transcriptional stimulator signal transducer
and activator of transcription (STAT)-1, and induces the
association of p65 NF-κB with histone deacetylase 1, thus
repressing cytokine production [29]. A reduction of
Table 4 Odds ratio and 95% CI for MetS score (number of
MetS components) according to tertiles of serum sTWEAK
concentrations
Tertiles of sTWEAK concentrations
MetS score
1st tertile 2nd tertile 3rd tertile
<453.1 ng/mL 453.1 to<706.4 ng/mL ≥706.4 ng/mL
Crude model:
2 vs ≤1 2.15 (0.96 - 4.79) 0.96 (0.49 - 1.88) 1.00 [Ref.]
3 vs ≤1 2.42 (1.06 - 5.51) 1.11 (0.56 - 2.22) 1.00 [Ref.]
≥4 vs ≤1 3.88 (1.66 - 9.06) 1.11 (0.52 - 2.36) 1.00 [Ref.]
Model 1:
2 vs ≤1 2.84 (1.22 - 6.62) 1.26 (0.62 - 2.58) 1.00 [Ref.]
3 vs ≤1 2.90 (1.23 - 6.81) 1.39 (0.66 - 2.90) 1.00 [Ref.]
≥4 vs ≤1 4.50 (1.87 - 10.82) 1.33 (0.61 - 2.93) 1.00 [Ref.]
Model 2:
2 vs ≤1 2.60 (1.09 - 6.22) 1.24 (0.60 - 2.58) 1.00 [Ref.]
3 vs ≤1 2.83 (1.16 - 6.87) 1.45 (0.67 - 3.01) 1.00 [Ref.]
≥4 vs ≤1 6.39 (2.42 - 16.85) 1.92 (0.80 - 4.61) 1.00 [Ref.]
Results expressed as odds ratios (95% CI) for the number of MetS components
from logistic regression analysis. Sample size of each group of MetS components
score is as follows: ≤1, n = 62; 2, n = 156; 3, n = 130; ≥4, n = 104. Abbreviations:
MetS Metabolic Syndrome, sTWEAK soluble TNF-like weak inducer of apoptosis.
Crude model: unadjusted; Model 1: Adjusted for gender and age: Model 2:
Additionally adjusted for family history of diabetes and premature CHD
(yes/no), educational level (primary education vs secondary/higher education),
alcohol intake (g alcohol/d), smoking (current/not-current), physical activity
(sedentary vs active) and eGFR.
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has also been postulated. Endothelial dysfunction is the
initial pathophysiological step in the progression of vascu-
lar damage that precedes and leads to clinically visible
CVD [30]. Under these conditions, Fn14 expression is in-
creased in the endothelium. Recently, we reported in-
creased Fn14 expression in human adipocytes from
severely obese subjects [31]. These cells also showed an
increase in Fn14 expression after inflammatory stimula-
tion, thus increasing availability for the sTWEAK ligand,
which could lead to a peripheral reduction in serum
sTWEAK [26,27]. An alternative hypothesis proposes the
involvement of CD163, a monocyte-macrophage surface
receptor which seems to act as a scavenger receptor for
sTWEAK [32]. Thus, the reduction in sTWEAK could be
related to the presence of sCD163, which is up-regulated
in patients with CKD and also in obese subjects [33-35].
This incremental increase could enable sTWEAK degrad-
ation by inflammatory macrophages, leading to decreased
sTWEAK levels and the reduction in the sTWEAK/
sCD163 ratio observed in such diseases as CKD [35].
Thus, low sTWEAK levels may be related to the degree of
macrophage activation.
In our study, we found that reduced levels of sTWEAK
were not only related to abdominal obesity, but also tosuch other MetS components as hyperglycemia and
hypertriglyceridemia. In this regard, we also found that
in human studies, changes in circulating free fatty acids
can influence circulating levels of sTWEAK, indicating
that lipotoxicity could be an important factor that regu-
lates sTWEAK levels in an inverse manner [27]. Our
findings with regard to hyperglycemia are in line with
previous studies reporting an inverse association between
sTWEAK and such glucose metabolism-related parame-
ters as fasting glucose and HOMA-IR [5,10,15,16]. In fact,
impaired fasting plasma glucose levels are recognized risk
factors for the development of T2D [36]. Interestingly, in
a large prospective nested case–control study we found
that reduced sTWEAK levels were associated with T2D
incidence [16]. Consistent with our findings, in a study of
60 individuals with chronic hemodialysis (32 had T2D)
and 60 controls (30 had T2D), the sTWEAK concentra-
tions in T2D patients on hemodialysis were lower [10].
Conversely, in vitro studies showed that NF-κB activation
affects TWEAK-induced insulin resistance by attenuating
the action of insulin in hepatocytes [37]. Anyhow, in vivo
experiments or animal models may help to clarify the ef-
fect of TWEAK on insulin resistance.
At the present time, how TWEAK binding to Fn14
can have such diverse cell-type specific biological effects
is not understood, but the differential activation of intra-
cellular signalling cascades is likely to be one explanation.
TWEAK can have either positive (beneficial) or negative
(detrimental) biological effects, depending on the type of
cell, tissue injury and/or the stage of the disease [3,4].
Thus, considering these observations as a whole, we
suggest that TWEAK contributes to the inflammatory/
anti-inflammatory imbalance observed in obesity, par-
ticularly abdominal-visceral obesity and the insulin re-
sistance state, and largely explains the association of
TWEAK with hyperglycemia [38] and the future devel-
opment of T2D. The examination of the biological
mechanisms through which sTWEAK improves insulin
sensitivity has demonstrated that, in visceral adipocytes,
treatment with sTWEAK ameliorates TNFα-induced in-
sulin resistance on glucose uptake [39,40]. This occurs
because it abolishes the stimulatory effect of TNFα on
JNK1/2 kinase, which is directly involved in the develop-
ment of insulin resistance [41]. This effect is at least partly
produced by a reduction in the cellular concentration of
TRAF2, leading to a curbing of TNFα intracellular signal-
ing events. Furthermore, this modulation of TNFα-
induced changes in insulin sensitivity was found to be
associated with an increase in the activity of PP2A, a Ser/
Thr phosphatase, known to negatively regulate cytokine
signaling [39]. Additionally, in human subcutaneous adi-
pocytes, sTWEAK exerts a modulatory effect on TNFα-
induced cytokine production by inhibiting the MAPK and
NF-κB signalling cascades commonly used by TNFα [27].
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TNFα activity has been observed in such pathologies as
rheumatoid arthritis [42], ischemic stroke [43] and sev-
eral tumour epithelial cell lines [44], suggesting general
competitive behaviour between sTWEAK and TNFα.
Lower levels of sTWEAK have been reported in young
individuals with primary hypertension [11]. However,
our study conducted in an older population did not pro-
vide any evidence to support that reduced levels of
sTWEAK are associated with hypertension. The fact that
the majority of subjects (90%) were hypertensive might
partly explain the lack of associations observed between
sTWEAK and the hypertension component of the MetS.
Notwithstanding the results observed, we should point
out that our study has several limitations that should be
kept in mind. Firstly, a major limitation is that the popula-
tion studied consisted of elderly Mediterranean Caucasian
individuals at high risk for CVD, so our findings cannot
be extrapolated to other age groups or ethnicities. Sec-
ondly, although rare, we could not completely discard the
presence of coronary heart disease in our population
explaining the associations observed, given that neither
echocardiography nor stress testing were systematically
performed in our cohort. Finally, another limitation of our
study is inherent to the study design. Because of the
cross-sectional nature, conclusions on a cause/effect rela-
tionship cannot be drawn.
In conclusion, in the present study we have demon-
strated that low TWEAK concentrations are associated
with increased risk of MetS, and this relationship was
mainly mediated by abdominal obesity, hyperglycemia
and hypertriglyceridemia. These findings suggest that
sTWEAK may have a key role in the development of
these metabolic disturbances, supporting the concept
that sTWEAK may be considered as a potential novel
biomarker of MetS with a putative protective effect. Fur-
ther longitudinal studies are warranted to confirm these
results in different populations.
Abbreviations
TWEAK: Soluble TNF-like weak inducer of apoptosis; mTWEAK: Full length
TWEAK isoform; sTWEAK: Soluble TWEAK isoform; Fn14: Fibroblast growth
factor-inducible 14; PAD: Peripheral artery disease; HOMA-IR: Homeostasis
model assessment of insulin resistance; T1D: Type 1 diabetes; T2D: Type 2
diabetes; MetS: Metabolic syndrome; CHD: Coronary heart disease;
CVD: Cardiovascular disease; BMI: Body mass index; LDL: Low-density
lipoprotein; HDL: High-density lipoprotein; IDF: International Diabetes
Federation; AHA/NHLBI: American Heart Association/National Heart, Lung, and
Blood Institute; METs: Metabolic Equivalents; NF-κB: Nuclear factor kappa B.
Competing interests
The authors have no conflict of interest affecting the conduct or reporting of
the work submitted.
Authors’ contributions
AD-L and JS-S had full access to all the data in the study and take full
responsibility for the integrity and accuracy of the data analysis. Study
concept and design: MAM-G, RE, and JS-S Analysis and interpretation of
data: AD-L, MB, MRCH, JV, MAM-G, and JS-S Drafting of the manuscript:AD-L, MRCH, and JS-S Statistical analysis: AD-L, MB, and JS-S Critical
revision of the manuscript for important intellectual content: All authors
critically revised and approved the final version of the manuscript.Acknowledgements
CIBERobn and CIBERdem is an initiative of ISCIII, Madrid, Spain. This study
was funded in part by the Spanish Ministry of Health (ISCIII), PI11/00049,
PI1001407, G03/140, RD06/0045, FEDER (FondoEuropeo de Desarrollo
Regional). None of the funding sources played a role in the design,
collection, analysis or interpretation of the data or in the decision to submit
the manuscript for publication. The Human Nutrition Unit belongs to the
Centre Català de la Nutrició, Institutd’Estudis Catalans, Catalonia. Matilde
Rodriguez Chacon is supported by a research stabilization program (CP06/
00119) from the Instituto de Salud Carlos III (ISCIII), co-financed by the Institut
Català de Salut (ICS) of Catalonia.
Author details
1Human Nutrition Unit, Faculty of Medicine and Health Sciences, IISPV,
Universitat Rovira i Virgili, C/ Sant Llorenç, 21, Reus, Tarragona 43201, Spain.
2CIBERobn Physiopathology of Obesity and Nutrition, Institute of Health
Carlos III, Madrid, Spain. 3The Biomedical Research Centres Network for
Diabetes and Associated Metabolic Disorders (CIBERDEM), University Hospital
of Tarragona Joan XXIII, IISPV, Universitat Rovira i Virgili, Tarragona, Spain.
4Department of Internal Medicine, Hospital Clinic, Institut d’Investigació
Biomèdica August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona,
Spain. 5Primary Health Care Centre of Tafalla, Tafalla, Spain. 6Cardiovascular
Risk and Nutrition Research Group (CARIN), Research Programme in
Inflammatory and Cardiovascular Disorders (RICAD), IMIM (Hospital del Mar
Medical Research Institute), Barcelona, Spain. 7Department of Preventive
Medicine and Public Health, School of Medicine, University of Valencia,
Valencia, Spain.
Received: 4 December 2013 Accepted: 20 February 2014
Published: 24 February 2014References
1. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I,
Browning JL: TWEAK, a new secreted ligand in the tumor necrosis factor
family that weakly induces apoptosis. J Biol Chem 1997, 272(51):32401–32410.
2. Sanchez-Niño MD, Benito-Martin A, Gonçalves S, Sanz AB, Ucero AC,
Izquierdo MC, Ramos AM, Berzal S, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A:
TNF superfamily: a growing saga of kidney injury modulators. Mediators
Inflamm 2010, doi:10.1155/2010/182958.
3. Wiley SR, Winkles JA: TWEAK, a member of the TNF superfamily, is a
multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine
Growth Factor Rev 2003, 14(3–4):241–249.
4. Winkles JA: The TWEAK-Fn14 cytokine-receptor axis: discovery, biology
and therapeutic targeting. Nat Rev Drug Discov 2008, 7(5):411–425.
5. Blanco-Colio LM, Martin-Ventura JL, Munoz-Garcia B, Orbe J, Paramo JA, Michel
JB, Ortiz A, Meilhac O, Egido J: Identification of soluble tumor necrosis factor-
like weak inducer of apoptosis (sTWEAK) as a possible biomarker of
subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27(4):916–922.
6. Chorianopoulos E, Rosenberg M, Zugck C, Wolf J, Katus HA, Frey N: Decreased
soluble TWEAK levels predict an adverse prognosis in patients with chronic
stable heart failure. Eur J Heart Fail 2009, 11(11):1050–1056.
7. Jelic-Ivanovic Z, Bujisic N, Spasic S, Bogavac-Stanojevic N, Spasojevic-Kalimanovska
V, Kotur-Stevuljevic J: Circulating sTWEAK improves the prediction of coronary
artery disease. Clin Biochem 2009, 42(13–14):1381–1386.
8. Chorianopoulos E, Jarr K, Steen H, Giannitsis E, Frey N, Katus HA: Soluble
TWEAK is markedly upregulated in patients with ST-elevation myocardial
infarction and related to an adverse short-term outcome. Atherosclerosis
2010, 211(1):322–326.
9. Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-
Ventura JL, Egido J, Gaussem P, Emmerich J, Michel JB, Blanco-Colio LM,
Meilhac O: Peripheral artery disease is associated with a high CD163/
TWEAK plasma ratio. Arterioscler Thromb Vasc Biol 2010, 30(6):1253–1262.
10. Kralisch S, Ziegelmeier M, Bachmann A, Seeger J, Lossner U, Bluher M,
Stumvoll M, Fasshauer M: Serum levels of the atherosclerosis biomarker
sTWEAK are decreased in type 2 diabetes and end-stage renal disease.
Atherosclerosis 2008, 199(2):440–444.
Díaz-López et al. Cardiovascular Diabetology 2014, 13:51 Page 9 of 9
http://www.cardiab.com/content/13/1/5111. Karadurmus N, Tapan S, Cakar M, Naharci I, Celik T, Tasci I, Sayin S, Dogan T,
Turker T, Erbil MK, Saglam K: Lower plasma soluble TWEAK concentration
in patients with newly diagnosed hypertension. Clin Invest Med 2012,
35(1):E20–E26.
12. Yilmaz MI, Carrero JJ, Ortiz A, Martin-Ventura JL, Sonmez A, Saglam M,
Yaman H, Yenicesu M, Egido J, Blanco-Colio LM: Soluble TWEAK plasma
levels as a novel biomarker of endothelial function in patients with
chronic kidney disease. Clin J Am Soc Nephrol 2009, 4(11):1716–1723.
13. Urbonaviciene G, Martin-Ventura JL, Lindholt JS, Urbonavicius S, Moreno JA,
Egido J, Blanco-Colio LM: Impact of soluble TWEAK and CD163/TWEAK
ratio on long-term cardiovascular mortality in patients with peripheral
arterial disease. Atherosclerosis 2011, 219(2):892–899.
14. Hassan SB, El-demery AB, Ahmed AI, Abukhalil RE: Soluble TWEAK and
cardiovascular morbidity and mortality in chronic kidney disease
patients. Arab J Nephrol Transplant 2012, 5(1):27–32.
15. Llaurado G, Gonzalez-Clemente JM, Maymo-Masip E, Subias D, Vendrell J,
Chacon MR: Serum Levels of TWEAK and Scavenger Receptor CD163 in
Type 1 Diabetes Mellitus: Relationship with Cardiovascular Risk Factors.
A case–control Study. PLoS One 2012, 7(8):e43919.
16. Diaz-Lopez A, Maymo-Masip E, Bullo M, Chacon MR, Martinez-Gonzalez MA,
Estruch R, Vendrell J, Basora J, Diez-Espino J, Covas MI, Salas-Salvado J:
Serum sTWEAK concentrations and risk of developing type 2 diabetes in
a high cardiovascular risk population: a nested case–control study. J Clin
Endocrinol Metab 2013, 98(8):3482–3490.
17. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R: Metabolic
syndrome a comprehensive perspective based on interactions between
obesity, diabetes, and inflammation. Circulation 2005, 111(11):1448–1454.
18. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia
E, Ruiz Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L,
Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA,
PREDIMED Study Investigators: Primary prevention of cardiovascular
disease with a Mediterranean diet. N Engl J Med 2013, 368(14):1279–1290.
19. Fernandez-Ballart JD, Pinol JL, Zazpe I, Corella D, Carrasco P, Toledo E, Perez-
Bauer M, Martinez-Gonzalez MA, Salas-Salvado J, Martin-Moreno JM: Relative
validity of a semi-quantitative food-frequency questionnaire in an elderly
Mediterranean population of Spain. Br J Nutr 2010, 103(12):1808–1816.
20. Elosua R, Marrugat J, Molina L, Pons S, Pujol E: Validation of the Minnesota
leisure time physical activity questionnaire in Spanish men. The
MARATHOM investigators. Am J Epidemiol 1994, 139(12):1197–1209.
21. Redon J, Coca A: Guidelines for the diagnosis, evaluation and treatment
of hypertension: the point of view of the Spanish Society of
Hypertension. Med Clin (Barc) 2003, 121(19):739–740.
22. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI,
Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic
Kidney Disease Epidemiology Collaboration): A new equation to estimate
glomerular filtration rate. Ann Intern Med 2009, 150(9):604–612.
23. Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart
J, James WPT, Loria CM, Smith SC: Harmonizing the metabolic syndrome a
joint interim statement of the International Diabetes Federation Task
Force on Epidemiology and Prevention; National Heart, Lung, and Blood
institute; American Heart Association; World Heart Federation;
International Atherosclerosis Society; and International Association for
the Study of Obesity. Circulation 2009, 120(16):1640–1645.
24. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM:
Metabolic syndrome and risk of incident cardiovascular events and
death: a systematic review and meta-analysis of longitudinal studies.
J Am Coll Cardiol 2007, 49(4):403–414.
25. Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, Eyileten T, Caglar K, Oguz Y,
Vural A, Çakar M: Soluble TWEAK and PTX3 in nondialysis CKD patients:
impact on endothelial dysfunction and cardiovascular outcomes. Clin J
Am Soc Nephrol 2011, 6(4):785–792.
26. Vendrell J, Maymo-Masip E, Tinahones F, Garcia-Espana A, Megia A, Caubet
E, Garcia-Fuentes E, Chacon MR: Tumor necrosis-like weak inducer of
apoptosis as a proinflammatory cytokine in human adipocyte cells:
up-regulation in severe obesity is mediated by inflammation but not
hypoxia. J Clin Endocrinol Metab 2010, 95(6):2983–2992.
27. Maymó-Masip E, Fernández-Veledo S, García-España A, Vázquez-Carballo A,
Tinahones FJ, García-Fuentes E, Garrido-Sanchez L, Rodríguez MM, Vendrell
J, Chacón MR: The rise of soluble TWEAK levels in severely obese subjects
after bariatric surgery May affect adipocyte-cytokine production induced
by TNFα. J Clin Endocrinol Metab 2013, 98(8):E1323–E1333.28. Tiller G, Fischer-Posovszky P, Laumen H, Finck A, Skurk T, Keuper M, Brinkmann
U, Wabitsch M, Link D, Hauner H: Effects of TWEAK (TNF superfamily member
12) on differentiation, metabolism, and secretory function of human primary
preadipocytes and adipocytes. Endocrinology 2009, 150(12):5373–5383.
29. Maecker H, Varfolomeev E, Kischkel F, Lawrence D, LeBlanc H, Lee W, Hurst
S, Danilenko D, Li J, Filvaroff E: TWEAK attenuates the transition from
innate to adaptive immunity. Cell 2005, 123(5):931–944.
30. Vita JA, Keaney JF: Endothelial function a barometer for cardiovascular
risk? Circulation 2002, 106(6):640–642.
31. Chacon MR, Richart C, Gomez JM, Megia A, Vilarrasa N, Fernandez-Real JM,
Garcia-Espana A, Miranda M, Masdevall C, Ricard W, Caubet E, Soler J,
Vendrell J: Expression of TWEAK and its receptor Fn14 in human
subcutaneous adipose tissue. Relationship with other inflammatory
cytokines in obesity. Cytokine 2006, 33(3):129–137.
32. Bover LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB,
Arap W, Pasqualini R: A previously unrecognized protein-protein interaction
between TWEAK and CD163: potential biological implications. J Immunol
2007, 178(12):8183–8194.
33. Fjeldborg K, Christiansen T, Bennetzen M, Møller HJ, Pedersen SB, Richelsen
B: The macrophage specific serum marker, soluble CD163, is increased in
obesity and reduced after dietary induced weight loss. Obesity 2013.
doi:10.1002/oby.20376. [Epub ahead of print].
34. Al-Daghri NM, Al-Attas OS, Bindahman LS, Alokail MS, Alkharfy KM, Draz HM,
Yakout S, McTernan PG, Sabico S, Chrousos GP: Soluble CD163 is associated
with body mass index and blood pressure in hypertensive obese Saudi
patients. Eur J Clin Invest 2012, 42(11):1221–1226.
35. Valdivielso JM, Coll B, Martín-Ventura JL, Moreno JA, Egido J, Fernández E,
Blanco-Colio LM: Soluble TWEAK is associated with atherosclerotic
burden in patients with chronic kidney disease. J Nephrol 2013, 28:0.
doi:10.5301/jn.5000245. [Epub ahead of print].
36. Tirosh A, Shai I, Tekes-Manova D, Israeli E, Pereg D, Shochat T, Kochba I,
Rudich A: Normal fasting plasma glucose levels and type 2 diabetes in
young men. N Engl J Med 2005, 353(14):1454–1462.
37. Feng F, Wang L, Albanese N, Holmes A, Xia P: Tumor necrosis factor-like
weak inducer of apoptosis attenuates the action of insulin in hepatocytes.
Endocrinology 2008, 149(4):1505–1513.
38. Chu CS, Lee KT, Cheng KH, Lee MY, Kuo HF, Lin TH, Su HM, Voon WC, Sheu SH,
Lai WT: Postchallenge responses of nitrotyrosine and TNF-alpha during 75-g
oral glucose tolerance test are associated with the presence of coronary
artery diseases in patients with prediabetes. Cardiovasc Diabetol 2012, 11:21.
39. Vazquez-Carballo A, Ceperuelo-Mallafré V, Chacon MR, Maymo-Masip E,
Lorenzo M, Porras A, Vendrell J, Fernandez-Veledo S: Tweak prevents TNF-
α-induced insulin resistance through PP2A activation in human
adipocytes. Am J Physiol Endocrinol Metab 2013, 305(1):E101–112.
40. Leguisamo NM, Lehnen AM, Machado UF, Okamoto MM, Markoski MM,
Pinto GH, Schaan BD: GLUT4 content decreases along with insulin
resistance and high levels of inflammatory markers in rats with
metabolic syndrome. Cardiovasc Diabetol 2012, 11:100.
41. Fernández-Veledo S, Vila-Bedmar R, Nieto-Vazquez I, Lorenzo M: c-Jun
N-terminal kinase 1/2 activation by tumor necrosis factor-α induces insulin
resistance in human visceral but not subcutaneous adipocytes: reversal by
liver X receptor agonists. J Clin Endocrinol Metab 2009, 94(9):3583–3593.
42. Yamana J, Morand EF, Manabu T, Sunahori K, Takasugi K, Makino H,
Yamamura M: Inhibition of TNF-induced IL-6 by the TWEAK-Fn14 interaction
in rheumatoid arthritis fibroblast like synoviocytes. Cell Immunol 2012,
272(2):293–298.
43. Echeverry R, Wu F, Haile WB, Wu J, Yepes M: The cytokine tumor necrosis
factor-like weak inducer of apoptosis and its receptor fibroblast growth
factor-inducible 14 have a neuroprotective effect in the central nervous
system. J Neuroinflammation 2012, 9(1):45.
44. Wicovsky A, Salzmann S, Roos C, Ehrenschwender M, Rosenthal T,
Siegmund D, Henkler F, Gohlke F, Kneitz C, Wajant H: TNF-like weak
inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling.
Cell Death Differ 2009, 16(11):1445–1459.
doi:10.1186/1475-2840-13-51
Cite this article as: Díaz-López et al.: Reduced circulating sTWEAK levels
are associated with metabolic syndrome in elderly individuals at high
cardiovascular risk. Cardiovascular Diabetology 2014 13:51.
